ABSTRACT
Prostate cancer cells are characterized by a remarkably low proliferative rate and the production of high levels of prostate-specific proteases. Protein-based toxins are attractive candidates for prostate cancer therapy because they kill cells via proliferation-independent mechanisms. However, the non-specific cytotoxicity of these potent cytotoxins must be redirected to avoid toxicity to normal tissues. Prostate-Specific Membrane Antigen (PSMA) is membrane-bound carboxypeptidase that is highly expressed by prostate cancer cells. Potent dipeptide PSMA inhibitors have been developed that can selectively deliver and concentrate imaging agents within prostate cancer cells based on continuous PSMA internalization and endosomal cycling. On this basis, we conjugated a PSMA inhibitor to the apoptosis-inducing human protease Granzyme B and the potent Pseudomonas exotoxin protein toxin fragment, PE35. We assessed selective PSMA binding and entrance into tumor cell to induce cell death. We demonstrated these agents selectively bound to PSMA and became internalized. PSMA-targeted PE35 toxin was selectively toxic to PSMA producing cells in vitro. Intratumoral and intravenous administration of this toxin produced marked tumor killing of PSMA-producing xenografts with minimal host toxicity. These studies demonstrate that urea-based PSMA inhibitors represent a simpler, less expensive alternative to antibodies as a means to deliver cytotoxic proteins to prostate cancer cells.
Subject(s)
Drug Delivery Systems , Immunotoxins/administration & dosage , Kallikreins , Prostate-Specific Antigen , Prostatic Neoplasms/drug therapy , Urea , Carboxypeptidases/metabolism , Cell Line, Tumor , Humans , Kallikreins/antagonists & inhibitors , Kallikreins/metabolism , Male , Prostate-Specific Antigen/antagonists & inhibitors , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/metabolismABSTRACT
Positron emission tomography (PET) imaging with radiotracers that target translocator protein 18 kDa (TSPO) has become a popular approach to assess putative neuroinflammatory processes and associated microglia activation in psychotic illnesses. It remains unclear, however, whether TSPO imaging can accurately capture low-grade inflammatory processes such as those present in schizophrenia and related disorders. Therefore, we evaluated the validity of TSPO as a disease-relevant marker of inflammation using a translational approach, which combined neurodevelopmental and neurodegenerative mouse models with PET imaging in patients with recent-onset schizophrenia and matched controls. Using an infection-mediated neurodevelopmental mouse model, we show that schizophrenia-relevant behavioral abnormalities and increased inflammatory cytokine expression are associated with reduced prefrontal TSPO levels. On the other hand, TSPO was markedly upregulated in a mouse model of acute neurodegeneration and reactive gliosis, which was induced by intrahippocampal injection of kainic acid. In both models, the changes in TSPO levels were not restricted to microglia but emerged in various cell types, including microglia, astrocytes and vascular endothelial cells. Human PET imaging using the second-generation TSPO radiotracer [11C]DPA-713 revealed a strong trend towards reduced TSPO binding in the middle frontal gyrus of patients with recent-onset schizophrenia, who were previously shown to display increased levels of inflammatory cytokines in peripheral and central tissues. Together, our findings challenge the common assumption that central low-grade inflammation in schizophrenia is mirrored by increased TSPO expression or ligand binding. Our study further underscores the need to interpret altered TSPO binding in schizophrenia with caution, especially when measures of TSPO are not complemented with other markers of inflammation. Unless more selective microglial markers are available for PET imaging, quantification of cytokines and other inflammatory biomarkers, along with their molecular signaling pathways, may be more accurate in attempts to characterize inflammatory profiles in schizophrenia and other mental disorders that lack robust reactive gliosis.
Subject(s)
Receptors, GABA/metabolism , Schizophrenia/metabolism , Adult , Animals , Astrocytes/metabolism , Biomarkers/blood , Disease Models, Animal , Female , Humans , Inflammation/metabolism , Male , Mice , Mice, Inbred C57BL , Microglia/metabolism , Neuroimmunomodulation/physiology , Positron-Emission Tomography/methods , Receptors, GABA/analysis , Schizophrenia/diagnostic imagingABSTRACT
Metastasis is the complex process by which primary tumor cells migrate and establish secondary tumors in an adjacent or distant location in the body. Early detection of metastatic disease and effective therapeutic options for targeting these detected metastases remain impediments to effectively treating patients with advanced cancers. If metastatic lesions are identified early, patients might maximally benefit from effective early therapeutic interventions. Further, monitoring patients whose primary tumors are effectively treated for potential metastatic disease onset is also highly valuable. Finally, patients with metastatic disease can be monitored for efficacy of specific therapeutic interventions through effective metastatic detection techniques. Thus, being able to detect and visualize metastatic lesions is key and provides potential to greatly improve overall patient outcomes. In order to achieve these objectives, researchers have endeavored to mechanistically define the steps involved in the metastatic process as well as ways to effectively detect metastatic progression. We presently overview various preclinical and clinical in vitro and in vivo assays developed to more efficiently detect tumor metastases, which provides the foundation for developing more effective therapies for this invariably fatal component of the cancerous process.
Subject(s)
Antineoplastic Agents/therapeutic use , Neoplasms/drug therapy , Neoplasms/pathology , Animals , Disease Progression , Humans , Neoplasm MetastasisABSTRACT
BACKGROUND: Prostate-specific membrane antigen (PSMA) is a cell surface enzyme that is highly expressed in prostate cancer (PCa) and is currently being extensively explored as a promising target for molecular imaging in a variety of clinical contexts. Novel antibody and small-molecule PSMA radiotracers labeled with a variety of radionuclides for positron emission tomography (PET) imaging applications have been developed and explored in recent studies. METHODS: A great deal of progress has been made in defining the clinical utility of this class of PET agents through predominantly small and retrospective clinical studies. The most compelling data to date has been in the setting of biochemically recurrent PCa, where PSMA-targeted radiotracers have been found to be superior to conventional imaging and other molecular imaging agents for the detection of locally recurrent and metastatic PCa. RESULTS: Early data, however, suggest that initial lymph node staging before definitive therapy in high-risk primary PCa patients may be limited, although intraoperative guidance may still hold promise. Other examples of potential promising applications for PSMA PET imaging include non-invasive characterization of primary PCa, staging and treatment planning for PSMA-targeted radiotherapeutics, and guidance of focal therapy for oligometastatic disease. CONCLUSIONS: However, all of these indications and applications for PCa PSMA PET imaging are still lacking and require large, prospective, systematic clinical trials for validation. Such validation trials are needed and hopefully will be forthcoming as the fields of molecular imaging, urology, radiation oncology and medical oncology continue to define and refine the utility of PSMA-targeted PET imaging to improve the management of PCa patients.
Subject(s)
Antigens, Surface/metabolism , Glutamate Carboxypeptidase II/metabolism , Molecular Imaging , Positron-Emission Tomography , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/metabolism , Combined Modality Therapy , Humans , Male , Molecular Imaging/methods , Neoplasm Metastasis , Neoplasm Staging , Positron Emission Tomography Computed Tomography , Positron-Emission Tomography/methods , Prostatic Neoplasms/therapy , Radioactive Tracers , Radiopharmaceuticals/chemistry , Recurrence , Treatment OutcomeABSTRACT
Several lines of evidence suggest aberrant immune response in schizophrenia, including elevated levels of cytokines. These cytokines are thought to be produced by activated microglia, the innate immune cells of the central nervous system. However, increase in translocator protein 18 kDa (TSPO), a marker of activated glia, has not been found in patients with chronic schizophrenia using second-generation radiotracers and positron emission tomography (PET)-based neuroimaging. In this study we focused on patients with recent onset of schizophrenia (within 5 years of diagnosis). Quantified levels of TSPO in the cortical and subcortical brain regions using the PET-based radiotracer [(11)C]DPA-713 were compared between the patients and healthy controls. Markers of inflammation, including interleukin 6 (IL-6), were assessed in the plasma and cerebrospinal fluid (CSF) in these participants. We observed no significant change in the binding of [(11)C]DPA-713 to TSPO in 12 patients with recent onset of schizophrenia compared with 14 controls. Nevertheless, the patients with recent onset of schizophrenia showed a significant increase in IL-6 in both plasma (P<0.001) and CSF (P=0.02). The CSF levels of IL-6 were significantly correlated with the levels of IL-6 in plasma within the total study population (P<0.001) and in patients with recent onset of schizophrenia alone (P=0.03). Our results suggest that increased levels of IL-6 may occur in the absence of changed TSPO PET signal in the brains of medicated patients with recent onset of schizophrenia. Future development of PET-based radiotracers targeting alternative markers of glial activation and immune response may be needed to capture the inflammatory signature present in the brains of patients with early-stage disease.
Subject(s)
Brain/metabolism , Inflammation/blood , Inflammation/cerebrospinal fluid , Positron-Emission Tomography/methods , Schizophrenia/blood , Schizophrenia/cerebrospinal fluid , Acetamides , Adolescent , Adult , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Brain/diagnostic imaging , Brain Mapping/methods , Female , Humans , Inflammation/diagnostic imaging , Male , Pyrazoles , Pyrimidines , Schizophrenia/diagnostic imaging , Young AdultABSTRACT
The prostate-specific membrane antigen (PSMA) is a molecular target whose use has resulted in some of the most productive work toward imaging and treating prostate cancer over the past two decades. A wide variety of imaging agents extending from intact antibodies to low-molecular-weight compounds permeate the literature. In parallel there is a rapidly expanding pool of antibody-drug conjugates, radiopharmaceutical therapeutics, small-molecule drug conjugates, theranostics and nanomedicines targeting PSMA. Such productivity is motivated by the abundant expression of PSMA on the surface of prostate cancer cells and within the neovasculature of other solid tumors, with limited expression in most normal tissues. Animating the field is a variety of small-molecule scaffolds upon which the radionuclides, drugs, MR-detectable species and nanoparticles can be placed with relative ease. Among those, the urea-based agents have been most extensively leveraged, with expanding clinical use for detection and more recently for radiopharmaceutical therapy of prostate cancer, with surprisingly little toxicity. PSMA imaging of other cancers is also appearing in the clinical literature, and may overtake FDG for certain indications. Targeting PSMA may provide a viable alternative or first-line approach to managing prostate and other cancers.
Subject(s)
Antigens, Surface/chemistry , Glutamate Carboxypeptidase II/chemistry , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/therapy , Animals , Crystallography, X-Ray , Drug Design , Humans , Magnetic Resonance Imaging , Male , Mice , Models, Molecular , Molecular Imaging/methods , Nanomedicine/methods , Nanomedicine/trends , Nanoparticles/chemistry , Neoplasm Metastasis , Neoplasm Transplantation , Positron-Emission Tomography , Radiopharmaceuticals/chemistry , Theranostic Nanomedicine , Urea/chemistryABSTRACT
D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), a glycosphingolipid synthesis inhibitor, holds promise for the treatment of atherosclerosis and cardiac hypertrophy but rapid in vivo clearance has severely hindered translation to the clinic. To overcome this impediment, we used a materials-based delivery strategy wherein D-PDMP was encapsulated within a biodegradable polymer composed of poly ethylene glycol (PEG) and sebacic acid (SA). PEG-SA was formulated into nanoparticles that were doped with (125)I-labeled PEG to allow in vivo bio-distribution and release kinetics of D-PDMP to be determined by using γ-scintigraphy and subsequently, by mass spectrometry. Polymer-encapsulation increased the residence time of D-PDMP in the body of a treated mouse from less than one hour to at least four hours (and up to 48 h or longer). This substantially increased in vivo longevity provided by polymer encapsulation resulted in an order of magnitude gain in efficacy for interfering with atherosclerosis and cardiac hypertrophy in apoE-/- mice fed a high fat and high cholesterol (HFHC) diet. These results establish that D-PDMP encapsulated in a biodegradable polymer provides a superior mode of delivery compared to unconjugated D-PDMP by way of increased gastrointestinal absorption and increased residence time thus providing this otherwise rapidly cleared compound with therapeutic relevance in interfering with atherosclerosis, cardiac hypertrophy, and probably other diseases associated with the deleterious effects of abnormally high glycosphingolipid biosynthesis or deficient catabolism.
Subject(s)
Atherosclerosis/drug therapy , Cardiomegaly/drug therapy , Morpholines/administration & dosage , Animals , Aortic Diseases/blood , Aortic Diseases/drug therapy , Aortic Diseases/prevention & control , Apolipoproteins E/deficiency , Atherosclerosis/blood , Atherosclerosis/prevention & control , Capsules , Cardiomegaly/blood , Cholesterol, Dietary/toxicity , Decanoic Acids , Delayed-Action Preparations , Dicarboxylic Acids , Diet, Atherogenic , Drug Evaluation, Preclinical , Heart Ventricles/pathology , Inactivation, Metabolic , Iodine Radioisotopes/analysis , Lipids/blood , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Molecular Structure , Morpholines/pharmacokinetics , Nanoparticles/administration & dosage , Polyethylene Glycols , Tissue Distribution , Vascular Stiffness/drug effectsABSTRACT
Bipolar disorder (BD) is a debilitating mental illness characterized by severe fluctuations in mood, sleep, energy and executive functioning. Pharmacological studies of selective serotonin reuptake inhibitors and the monoamine system have helped us to clinically understand bipolar depression. Mood stabilizers such as lithium and valproic acid, the first-line treatments for bipolar mania and depression, inhibit glycogen synthase kinase-3 beta (GSK-3ß) and regulate the Wnt pathway. Recent investigations suggest that microglia, the resident immune cells of the brain, provide a physiological link between the serotonin system and the GSK-3ß/Wnt pathway through neuroinflammation. We review the pharmacological, translational and brain imaging studies that support a role for microglia in regulating neurotransmitter synthesis and immune cell activation. These investigations provide a model for microglia involvement in the pathophysiology and phenotype of BD that may translate into improved therapies.
Subject(s)
Bipolar Disorder , Inflammation , Microglia , Molecular Imaging , Neuropharmacology , Signal Transduction , Bipolar Disorder/drug therapy , Bipolar Disorder/immunology , Bipolar Disorder/metabolism , Humans , Inflammation/drug therapy , Inflammation/immunology , Inflammation/metabolism , Microglia/drug effects , Microglia/immunology , Microglia/metabolism , Signal Transduction/drug effects , Signal Transduction/immunology , Signal Transduction/physiologySubject(s)
Schizophrenia/cerebrospinal fluid , Superoxide Dismutase/cerebrospinal fluid , Adult , Amyloid beta-Peptides/cerebrospinal fluid , Case-Control Studies , Female , Follow-Up Studies , Humans , Linear Models , Male , Peptide Fragments/cerebrospinal fluid , Psychiatric Status Rating Scales , Superoxide Dismutase-1 , Young AdultABSTRACT
Glutamate carboxypeptidase II (GCPII) in the central nervous system is referred to as the prostate-specific membrane antigen (PSMA) in the periphery. PSMA serves as a target for imaging and treatment of prostate cancer and because of its expression in solid tumor neovasculature has the potential to be used in this regard for other malignancies as well. An overview of GCPII/PSMA in cancer, as well as a discussion of imaging and therapy of prostate cancer using a wide variety of PSMA-targeting agents is provided.
Subject(s)
Antigens, Surface , Glutamate Carboxypeptidase II , Molecular Imaging/methods , Neoplasms/diagnosis , Neoplasms/enzymology , Animals , Antigens, Surface/genetics , Antigens, Surface/metabolism , Gene Expression Regulation, Neoplastic , Glutamate Carboxypeptidase II/genetics , Glutamate Carboxypeptidase II/metabolism , Glutamic Acid/metabolism , Humans , Male , Neoplasms/genetics , Neoplasms/pathology , Prostate/enzymology , Prostate/metabolism , Prostate/pathology , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathologyABSTRACT
BACKGROUND: Adrenomyeloneuropathy (AMN) is the adult variant of X-linked adrenoleukodystrophy. The disease pathology is usually limited to spinal cord and peripheral nerves, and when this is the case, it is referred to as "pure" AMN. Histopathology shows cerebral involvement even in pure AMN; however, not much is known about the nature, extent, and clinical relevance of these findings. OBJECTIVE: To investigate brain involvement in AMN patients with normal MRI, employing multislice MR spectroscopic imaging. METHODS: Twelve men with pure AMN were compared with 19 age-matched healthy volunteers. Metabolite ratios (N-acetylaspartate [NAA]/choline [Cho], NAA/creatine [Cr], and Cho/Cr) were measured from seven brain regions. Global metabolite ratios were generated as an average of these seven regional ratios. The Expanded Disability Status Scale (EDSS) was used for neurologic evaluation. RESULTS: The patients with AMN showed reduced global NAA/Cho (AMN 1.40 +/- 0.16 vs controls 1.75 +/- 0.34; p = 0.003)) and global NAA/Cr (AMN 2.32 +/- 0.13 vs controls 2.62 +/- 0.43; p = 0.03). Regionally, NAA/Cho was lowered in the internal capsule (AMN 1.30 +/- 0.20 vs controls 1.69 +/- 0.37; p = 0.002) and in parieto-occipital white matter (AMN 1.45 +/- 0.19 vs controls 1.78 +/- 0.55; p = 0.04). NAA/Cr was lowered in parieto-occipital white matter (AMN 2.34 +/- 0.31 vs controls 2.83 +/- 0.71; p = 0.04). EDSS demonstrated an inverse association with global NAA/Cr (r = -0.65, p = 0.02) and NAA/Cr in centrum semiovale (r = -0.73, p = 0.006) and in parieto-occipital white matter (r = -0.64, p = 0.02). Cho/Cr was not significantly elevated. CONCLUSIONS: (1)H-MR spectroscopic imaging is able to detect biochemical abnormalities suggestive of axonal damage even in the brains of patients with pure adrenomyeloneuropathy. The axonopathy is most prominent in internal capsule and parieto-occipital white matter and may contribute to clinical disability.
Subject(s)
Adrenoleukodystrophy/metabolism , Aspartic Acid/analogs & derivatives , Axons/chemistry , Brain Chemistry , Choline/analysis , Creatine/analysis , Magnetic Resonance Spectroscopy , Adrenoleukodystrophy/pathology , Adult , Aspartic Acid/analysis , Axons/pathology , Biomarkers , Brain/pathology , Cross-Sectional Studies , Disability Evaluation , Female , Gait Disorders, Neurologic/etiology , Humans , Magnetic Resonance Imaging , Male , Middle AgedSubject(s)
Brain/pathology , Lung Neoplasms/diagnosis , Meninges/pathology , Meningioma/diagnosis , Spinal Neoplasms/diagnosis , Spine/pathology , Adult , Cognition Disorders/etiology , Female , Headache/etiology , Hearing Loss, Bilateral/etiology , Humans , Lumbosacral Region , Lung Neoplasms/secondary , Magnetic Resonance Imaging , Meningioma/radiotherapy , Meningioma/surgery , Neoplasm Recurrence, Local/diagnosis , Neoplasm, Residual/diagnosis , Remission Induction , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/surgery , Spine/surgery , Tomography, X-Ray Computed , Vision Disorders/etiologyABSTRACT
OBJECTIVE: We attempt to determine whether angiography is indicated in patients with suspected central nervous system (CNS) vasculitis who present with negative findings on MR imaging studies. CONCLUSION: MR imaging findings may be negative in the setting of CNS vasculitis confirmed on angiography, indicating that advanced imaging techniques tailored to detect infarction (i.e., fluid-attenuated inversion recovery, diffusion-weighted, and perfusion imaging) may be necessary to enhance the sensitivity of an MR study and that despite the high sensitivity of MR imaging for CNS vasculitis, angiography may still be required to render an accurate diagnosis.
Subject(s)
Magnetic Resonance Imaging , Vasculitis, Central Nervous System/diagnosis , Cerebral Angiography , Female , Humans , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity , Vasculitis, Central Nervous System/diagnostic imagingABSTRACT
Benign neurofibromas undergo sarcomatous transformation in approximately 5% of patients with neurofibromatosis type I. The clinical and radiologic diagnosis of sarcomatous change remains difficult. Positron emission tomography with F-18 fluorodeoxyglucose is a method to assess increased glucose metabolism in malignant tissue such as sarcomas. In this case report, positron emission tomography accurately distinguished malignant from benign neurofibromas. The technique may be useful as a noninvasive screening tool for malignant transformation of neurofibromas.
Subject(s)
Neurofibromatosis 1/diagnostic imaging , Pelvic Neoplasms/diagnostic imaging , Peripheral Nervous System Neoplasms/diagnostic imaging , Sarcoma/diagnostic imaging , Tomography, Emission-Computed/methods , Adult , Cell Transformation, Neoplastic , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Neurofibromatosis 1/pathology , Neurofibromatosis 1/surgery , Pelvic Neoplasms/pathology , Pelvic Neoplasms/surgery , Peripheral Nervous System Neoplasms/pathology , Peripheral Nervous System Neoplasms/surgery , Sarcoma/pathology , Sarcoma/surgery , Sensitivity and SpecificityABSTRACT
BACKGROUND AND PURPOSE: Chordoid glioma is a new clinicopathologic entity that occurs in the region of the hypothalamus/anterior third ventricle. The aims of this study were to describe the characteristic radiographic features of chordoid glioma, identify specific imaging features that may enable differentiation of chordoid glioma from other suprasellar tumors, and increase neuroradiologists' awareness of this newly described tumor, facilitating prospective diagnosis. METHODS: CT scans and/or MR images of six patients with chordoid glioma were reviewed retrospectively to determine whether any characteristic radiographic features would emerge. Reports of the clinical presentation, pathologic findings, and radiographic findings of another six patients were reviewed and included, for a total patient population of 12 (mean age +/- SD, 46 +/- 13 years). RESULTS: Imaging features were strikingly similar for all tumors. In each case, the mass was ovoid, was well circumscribed, was located in the region of the hypothalamus/anterior third ventricle, and enhanced uniformly and intensely. Tumors were hyperdense to gray matter on CT scans and were isointense on T1-weighted MR images and slightly hyperintense on long-TR MR images. In two patients, vasogenic edema extended into the optic tracts, and in three, there was hydrocephalus. CONCLUSION: Chordoid glioma is a recently described unique histopathologic entity that has been added to the World Health Organization glioma classification scheme and must be included in the differential diagnosis of a suprasellar mass. Distinctive imaging features are its location, ovoid shape, hyperdensity on CT scans, and uniform intense contrast enhancement.
Subject(s)
Cerebral Ventricle Neoplasms/diagnosis , Glioma/diagnosis , Hypothalamic Neoplasms/diagnosis , Third Ventricle , Adult , Aged , Cerebral Ventricle Neoplasms/pathology , Cerebral Ventriculography , Chordoma/pathology , Female , Glioma/pathology , Humans , Hypothalamic Neoplasms/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Tomography, X-Ray ComputedABSTRACT
PURPOSE: The purpose of this work was to determine the optimal imaging parameters for minimization of metallic susceptibility artifacts during gradient echo (GRE) imaging. METHOD: We performed GRE imaging of titanium screws in a nickel-doped agarose gel phantom, systematically varying several parameters to characterize and quantify susceptibility artifacts. RESULTS: The greatest reduction in artifact size came from using a short TE; increasing the frequency matrix and decreasing the slice thickness also contributed substantially to reducing the artifact size. Whenever possible, implanted prostheses should be aligned with the main magnetic field to minimize artifact size. Parameters with negligible effect on artifact size included bandwidth, phase encode matrix, and field of view. CONCLUSION: Radiologists can easily adjust the above parameters in their imaging protocols to improve GRE image quality in patients with implanted metallic devices.
Subject(s)
Artifacts , Image Enhancement/methods , Magnetic Resonance Imaging/methods , Bone Screws , Gels , Humans , Magnetics , Metals , Nickel , Phantoms, Imaging , Prostheses and Implants , Sepharose , TitaniumABSTRACT
UNLABELLED: The objectives of this study were to synthesize neuronal nitric oxide synthase (NOS-I)-selective imaging agents based on the 2 potent, selective inhibitors AR-R 17443 [N-(4-((2-((phenylmethyl) (methyl)-amino)ethyl)phenyl)-2-thiophenecarboximidamide)] and AR-R 18512 [(N(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-2-thiophenecarboxim idamide)] in positron-emitting form and to evaluate regional brain uptake in rodents and primates. METHODS: [11C]AR-R 17443 and [11C]AR-R 18512 were produced by N-alkylation of the corresponding desmethyl precursors using [11C]iodomethane. Regional brain uptake of [11C]AR-R 17443 and [11C]AR-R 18512 was assayed in rats and NOS-I knockout mice, and PET was performed in baboons. Tracer kinetic modeling used a 2-compartment plasma and brain tissue model. RESULTS: Yields of [11C]AR-R 17443 and [11C]AR-R 18512 ranged from 8% to 16% at the end of synthesis, with specific activities of 50-178 GBq/micromol (1,350-4,800 Ci/mmol) at the end of synthesis. In rat cerebellum and cortex at 30 min after injection, [11C]AR-R 17443 showed 1.01 +/- 0.01 and 1.63 +/- 0.12 percentage injected dose per gram (%ID/g) uptake, respectively, whereas [11C]AR-R 18512 showed 0.88 +/- 0.01 and 1.30 +/- 0.07 %ID/g uptake, respectively. Attempts to block tracer uptake by pretreatment with the NOS-I-selective inhibitor 7-nitroindazole or the corresponding unlabeled inhibitor (or desmethyl precursor to AR-R 17443 of similar potency) were unsuccessful. A small but significant (20%) decrease in cerebellar uptake of [11C]AR-R 18512 was present in NOS-I knockout mice compared with control mice. PET of [11C]AR-R 18512 in baboons with concurrent regional cerebral blood flow (rCBF) determination before and after administration of blocker showed dose-related decreases in cerebellar uptake that were greater than or equal to decreases in rCBF. Plasma metabolites accounted for 27% of total activity at 30 min after injection. Kinetic modeling of binding potentials revealed a distribution volume of 334 in cerebral blood that dropped 51% after blocker administration. CONCLUSION: Rodent studies for [11C]AR-R 17443 and [11C]AR-R 18512 showed little evidence of specific NOS-I binding. In baboons, we detected a higher uptake of [11C]AR-R 18512 in the cerebellum than in the cortex (approximately 5%, accounting for decreased rCBF because of blockade), indicating minimal specific binding. Analogs of higher affinity are likely required if this class of agents is to prove viable for PET.
Subject(s)
Brain/diagnostic imaging , Brain/enzymology , Enzyme Inhibitors/pharmacokinetics , Isoquinolines/pharmacokinetics , Nitric Oxide Synthase/analysis , Tetrahydroisoquinolines , Thiophenes/pharmacokinetics , Tomography, Emission-Computed , Animals , Blood-Brain Barrier , Carbon Radioisotopes/pharmacokinetics , Enzyme Inhibitors/chemical synthesis , Isoquinolines/chemical synthesis , Male , Mice , Mice, Knockout , Models, Biological , Nitric Oxide Synthase/deficiency , Nitric Oxide Synthase Type I , Organ Specificity , Papio , Rats , Rats, Sprague-Dawley , Thiophenes/chemical synthesis , Tissue DistributionABSTRACT
PURPOSE: To use sodium 23 magnetic resonance (MR) imaging to quantify noninvasively total sodium in human muscle and to apply the technique in exercise and musculoskeletal disease. MATERIALS AND METHODS: Total [Na] sodium was determined from the ratio of the relaxation-corrected (23)Na signal intensities measured from short echo-time (0.4 msec) (23)Na images to those from an external saline solution reference. The method was validated with the blinded use of saline solutions of varying sodium concentrations. [Na] was measured in the calf muscles in 10 healthy volunteers. (23)Na MR imaging also was performed in two healthy subjects after exercise, two patients with myotonic dystrophy, and two patients with osteoarthritis. RESULTS: (23)Na MR imaging yielded a total [Na] value of 28.4 mmol/kg of wet weight +/- 3.6 (SD) in normal muscle, consistent with prior biopsy data. Spatial resolution was 0.22 mL, with signal-to-noise ratio of 10-15. Mean signal intensity elevations were 16% and 22% after exercise and 47% and 70% in dystrophic muscles compared with those at normal resting levels. In osteoarthritis, mean signal intensity reductions were 36% and 15% compared with those in unaffected knee joints. CONCLUSION: (23)Na MR imaging can be used to quantify total [Na] in human muscle. The technique may facilitate understanding of the role of the sodium-potassium pump and perfusion in normal and diseased muscle.
Subject(s)
Magnetic Resonance Imaging/methods , Muscle, Skeletal/metabolism , Muscular Diseases/diagnosis , Physical Exertion/physiology , Sodium/analysis , Adult , Algorithms , Analysis of Variance , Biopsy , Bone Diseases/diagnosis , Bone Diseases/metabolism , Electron Spin Resonance Spectroscopy , Fourier Analysis , Humans , Least-Squares Analysis , Male , Muscle Contraction/physiology , Muscle, Skeletal/anatomy & histology , Muscular Diseases/metabolism , Myotonic Dystrophy/diagnosis , Myotonic Dystrophy/metabolism , Osteoarthritis, Knee/diagnosis , Osteoarthritis, Knee/metabolism , Phantoms, Imaging , Reproducibility of Results , Signal Processing, Computer-Assisted , Single-Blind Method , Sodium ChlorideABSTRACT
The past decade has seen many new MR imaging techniques that have been applied to brain tumor imaging. As MR imaging is applied further to cellular and molecular imaging (e.g., imaging of gene transfer and expression), more possibilities for brain tumor diagnosis and treatment will become evident. The superior contrast, resolution, and lack of need for image coregistration suggest that MR imaging techniques may displace PET as the preeminent modality for studying brain and tumor physiology and chemistry for indications other than receptor-based imaging. Nevertheless, the new MR imaging techniques require further histologic, physiologic, and intraoperative validation in suitable animal models and in clinical studies, and should be used to complement PET. Application of echo-planar imaging and other fast imaging sequences can permit the merger of several MR imaging studies (e.g., perfusion imaging, DWI, and MRS(I) into a typical (1-hour) clinical time slot). Synergistic information provided by these new techniques might soon enable physicians to reach the ultimate goals of noninvasive tumor grading and avoidance of having to obtain a biopsy.